Fructosamine Test Projections at US$399.9 Million in 2034

Global fructosamine test market size was estimated to be US$ 266.3 million in 2023, and it is expected to grow at a compound annual growth rate (CAGR) of 3.8% over the course of the forecast period. As a result, it is anticipated that the overall market valuation would rise from US$ 275.9 million in 2024 to US$ 399.9 million in 2034.

Several factors are anticipated to drive the growth of the fructosamine test industry over the assessment period. These include increasing incidence of diabetes and obesity, growing awareness about fructosamine testing, and rising need for efficient blood glucose monitoring diagnostic tests.

Fructosamine testing has become a widely used method for measuring blood glucose. It does not require fasting and can be helpful when an HbA1c test is unreliable.

There has been a sharp rise in cases of diabetes during the last few years. For instance, according to the International Diabetes Federation, around 537 million adults were living with diabetes in 2021. This, in turn, is expected to uplift demand for fructose tests.

Seize Excellence Today: Claim Your Sample for Unmatched Efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-7030

Fructosamine testing is an important method that helps medical professionals monitor glycemic management in diabetics. The growing demand for these monitoring technologies highlights the need to address the expanding diabetes epidemic. It also shows the critical role innovative approaches, such as fructosamine testing, play in treating and reducing the effects of this chronic condition.

Another notable trend is the growing focus on fructosamine point-of-care diagnostics, which provide quick and easy glycemic control monitoring at the patient's location. This change speeds up the evaluation of fast-acting blood glucose levels, allowing for rapid medical choices.

Point-of-care testing minimizes the need for a large laboratory infrastructure by streamlining the diagnostic procedure and providing instant results. This trend supports proactive diabetes management by improving patient accessibility to timely healthcare information, which is the primary goal.

Point-of-care fructosamine tests are a major improvement in decentralized healthcare due to their accessibility and speed. They significantly promote quicker interventions and improve overall patient outcomes.

Key Takeaways from the Fructosamine Test Market Study

The global market for fructosamine test is set to attain a valuation of US$ 399.9 million in 2034
By disease indication, the diabetes II segment held a market share of about 59.4% in 2023.
By sample, the blood serum is expected to progress with a CAGR of 3.5%.
By end-user, the hospitals segment accounted for a revenue share of 29.8% in 2023.
North America dominates the global market with a share of around 31.5%.
The United States market value totaled US$ 74.7 million in 2023.
Demand in India is predicted to rise at 7.9% CAGR through 2034.

“The rising focus on personalized diabetes management and compliance with CLIA standards enhances the use of fructosamine tests in clinical laboratories. This, in turn, will boost the growth of the fructosamine test industry over the forecast period,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

The Top Key Companies Profiled in the Fructosamine Test Market

Beckman Coulter, Inc.
Randox Laboratories Ltd.
Fortress Diagnostics
KAMIYA BIOMEDICAL COMPANY
Abbexa
Weldon Biotech, Inc.
Eurolyser Diagnostica GmbH
F. Hoffmann-La Roche Ltd
Asahi Kasei Pharma Corporation (EKF DIAGNOSTICS)
LifeSpan BioSciences, Inc
Zhejiang Kangte Biotechnology Co., Ltd.
Diazyme
Abcam plc.
Weldon Biotech, Inc.
Bio Vision
Mybiosource

For instance,

In June 2023, Fortress Diagnostics created awareness with a focus on men's health testing awareness month and posted an article on diabetes and a higher risk of diabetes due to reduced rates of weight gain and accumulation of fat.

Fructosamine Test Market Outlook by Category

By Disease Indication: